Chimeric Therapeutics (ASX:CHM) said that its trial for CHM CDH17, a treatment candidate which targets CDH17, a cancer biomarker associated with poor prognosis and metastases in the most common gastrointestinal tumors, advanced to dose level 2, after no safety concerns or off target effects were observed at dose level 1, according to a Monday Australian bourse filing.
Dose level 2 has begun. One patient from the dose level 1 cohort remains with stable disease for the eighth month after the dose, which was 50 million cells, while in imageable tumor, the firm saw a shrinkage of around 18% over time.
The trial is a two-stage study designed to determine a recommended phase two dose of CHM CDH17 and evaluate its safety and objective response rate in patients with advanced colorectal cancer, gastric cancer, and intestinal neuroendocrine tumors.
Its shares fell 14% in recent trading on Monday.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.